Cell and Gene Therapy Catapult Appoints Board Members
This article was originally published in Scrip
Executive Summary
The UK organization Cell and Gene Therapy Catapult has appointed new non-executive directors Fiona Watt, Susan Foden and Steven Chatfield to its board. Watt has spent 20 years at the CRUK London Research Institute and helped establish the CRUK Cambridge Research Institute and Wellcome Trust Centre for stem cell research in Cambridge. Foden has been a non-executive director for various life science companies and currently holds non-executive positions at companies including British Technology Group plc., Vectura plc., Evgen Pharma plc and BerGenBio AS. Chatfield brings over 35 years' experience and previously held executive positions at the Health Protection Agency, Emergent BioSolutions, Microscience Ltd, Medeva plc, Evans Medical and Wellcome Biotechnology.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.